Michael Demeure, MD
Surgery · Newport Beach, CANPI 1629041579
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $36,610 of the $52,728 with a category attached, or 69.4%. 16 manufacturers reported payments, led by Eli Lilly at 51.1% of the total. Reporting peaked in 2023 at $17,572 and has fallen 75.2% since, to $4,353 in 2025. Among surgery clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 49 payments — averaging $1076.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$27K
- Corcept Therapeutics$9K
- Aadi Bioscience, Inc.$6K
- Array Biopharma Inc$4K
- Boehringer Ingelheim$3K
- Exelixis Inc.$2K
- plus $1K from 10 others
Across 167 payments — averaging $9602.07 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Aadi Bioscience, Inc.$1.3M
- Otsuka Pharmaceutical Co., Ltd.$162K
- Mirati Therapeutics, Inc.$62K
- Taiho Oncology, Inc.$47K
- Exelixis Inc.$24K
- Bayer$13K
What the payments were for
- Consulting fees$36,61069%
- Speaking & faculty fees$11,65822%
- Travel & lodging$2,8405%
- Food & beverage$1,6203%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 7 | $26,950 |
| Corcept Therapeutics | 14 | $8,946 |
| Aadi Bioscience, Inc. | 4 | $5,839 |
| Array Biopharma Inc | 1 | $4,200 |
| Boehringer Ingelheim | 1 | $3,060 |
| Exelixis Inc. | 9 | $2,237 |
| Bayer | 3 | $948 |
| Covidien LP | 2 | $162 |
| Roche Diagnostics Corporation | 1 | $136 |
| Mirati Therapeutics, Inc. | 1 | $109 |
| Baxter Healthcare | 1 | $36 |
| Acell, Inc. | 1 | $31 |
| Foundation Medicine, Inc. | 1 | $28 |
| AbbVie | 1 | $17 |
| Caris MPI, Inc. | 1 | $16 |
| Integra Lifesciences Corporation | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$52,728 in reported general payments places this provider in the 95th percentile of 2,363 surgery providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Levothyroxine Sodium | 65 | $544 |
| Oxycodone Hcl | 21 | $34 |
Paid to pharmacies, not to this prescriber.
Other surgery in Newport Beach
- Timothy ChuterSan Francisco$8.8M
- Santiago HorganSan Diego$2.8M
- Rock LiuHayward$1.6M
- David LouriePasadena$1.4M
- Andrea PakulaThousand Oaks$1.4M
- Siew-Ming LeeFresno$1.3M
- Beemen KhalilPalo Alto$1.1M
- John LiphamLos Angeles$942K
- Alexander NedopilLodi$682K
- Barry GardinerSan Ramon$602K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.